text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 27318-90-7 | Product Number: P1973


Purity: >98.0%(T)(HPLC)
  • Phendione
  • LDN-73794
1   37  
3   ≥40 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).

Product Number P1973
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__1__2H__6N__2O__2 = 210.19 
Physical State (20 deg.C) Solid
CAS RN 27318-90-7
Reaxys Registry Number 160532
PubChem Substance ID 135727031
MDL Number


Appearance Light yellow to Amber to Dark green powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 98.0 %
Properties (reference)
Melting Point 257 °C
Maximum Absorption Wavelength 251(MeOH) nm
Pictogram Pictogram
Signal Word Warning
Hazard Statements H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
Precautionary Statements P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ eye protection/ face protection.
P302 + P352 : IF ON SKIN: Wash with plenty of water.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P332 + P313 : If skin irritation occurs: Get medical advice/ attention.
Related Laws:
Transport Information:
HS Number 2933998090
Phendione and its Complexes: DNA Targeting Antitumor or Antimicrobial agents

1,10-Phenanthroline-5,6-dione (other names in biological references: Phendione, and LDN-73794) forms Ag(I) and Cu(II) phendio complexes. Phendione and its complexes have been reported to inhibit DNA synthesis, and exhibit antitumor, antimicrobial, and antifungal activities.1-4) In addition, phendione (LDN-73794 in the reference) inhibits LRRK2 (Leucine-rich repeat kinase 2) -G2019S that is a promising therapeutic target for the treatment of Parkinson's disease.5) (The product is for research purpose only.)


Aerobic Dehydrogenation of Secondary Amines with an Oxidative Bifunctional Quinone Catalyst


Typical Procedure: (Scheme1, R1 = H): A 25 mL flask is charged with 1,10-phenanthroline-5,6-dione (10.5 mg, 0.05 mmol) and 1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline (194.6 mg, 1.0 mmol) and anhydrous CH3CN (3.0 mL) is added. The flask is flushed with O2 and equipped with an O2 balloon. A well-dissolved solution of ZnI2 (7.98 mg, 0.025 mmol) and PPTS (37.7 mg, 0.15 mmol) in anhydrous CH3CN (1.0 mL) is then added. The reaction is stirred vigorously at room temperature for 24 h. The mixture is diluted in EtOAc (50 mL) and washed with 1M NaOH (25 mL). The aqueous phase is extracted with additional EtOAc (2 x 25 mL). The combined organic phases are washed with brine (25 mL), dried over Na2SO4, and concentrated. The residue is purified by column chromatography on silica gel (eluent: EtOAc/hexanes or EtOAc) to give 3,4-dihydro-6,7-dimethoxyisoquinoline (176.1 mg, 91% yield) as a viscous oil.


Synthesis of a Condensed-ring Conjugated Phenanthroline Metal Ligand with Electron-acceptor Properties

1,10-Phenanthroline-5,6-dione (0.618 g, 2.94 mmol) and 2,3-diamino-1,4-naphthoquinone hydrochloride (0.660 g, 2.94 mmol) are suspended in dry ethanol (40 mL). The mixture is refluxed for 1.5 h under a N2 atmosphere. A green solid is formed. The mixture is cooled to rt and the solid is filtered, washed with ethanol and diethyl ether. After drying under high vacuum, the desired lignad 1 (0.926 g, 87%) are obtained as a green powder.


PubMed Literature

Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents